Majority of Patients with Advanced Melanoma Remain Disease-Free Four Years Post-Neoadjuvant Immunotherapy

A recent study from The University of Texas MD Anderson Cancer Center has shed new light on the long-term efficacy of pre-surgical immunotherapy in advanced melanoma. The research, published in the Journal of Clinical Oncology, followed 30 patients with stage III melanoma who received a combination of immune checkpoint inhibitors—nivolumab and relatlimab—before surgical removal of tumors. After four years, 87% of these patients remained alive, with 80% showing no signs of cancer recurrence. Notably, those who experienced a significant tumor response before surgery had an even higher recurrence-free rate of 95%. This indicates that preoperative immunotherapy can effectively train the immune system to combat cancer cells, thereby reducing the likelihood of relapse.

The study also identified potential biomarkers associated with better outcomes. Patients with high pre-treatment levels of TIGIT or low levels of B7-H3 had a greater chance of remaining recurrence-free, paving the way for personalized treatment approaches in melanoma. The success of this combination therapy highlights the importance of neoadjuvant immunotherapy—administering treatment before surgery—to shrink tumors and stimulate the immune response, particularly in high-risk stage III cases.

Relatlimab, a LAG-3 inhibitor, was approved by the FDA in 2022 in combination with nivolumab based on positive results from the RELATIVITY-047 trial. Researchers are now exploring how biomarkers influence treatment response by utilizing advanced spatial profiling techniques. Collaboration with MD Anderson's James P. Allison Institute aims to further validate these biomarkers and understand their role in overcoming resistance.

Overall, these promising findings support the integration of immunotherapy into early treatment strategies for melanoma, offering hope for improved long-term survival and lower recurrence rates in patients with advanced disease.